Table 5. Antithrombotic regimens for post-KD coronary lesions stratified by risk level

Variables	Suggested regimen	Key references
Risk Level 1 (no involvement)	Stop aspirin after acute phase (6–8 wk) if stable	[1]
Risk Level 2 (dilation only)	Low-dose aspirin short-term; discontinue if normalized	[1–3]
Risk Level 3 (small CAA, z-score 2.5–5)	Long-term aspirin; consider dual therapy if high-risk features	[1]
Risk Level 4 (medium CAA, z-score 5–10)	Long-term low-dose aspirin; add clopidogrel for persistent or current medium CAA per AHA recommendations; consider anticoagulation if stasis or thrombosis risk is present.	[1–3]
Risk Level 5 (giant CAA ≥ 8 mm or z-score ≥ 10)	Aspirin + warfarin (typical INR 2.0–2.5 or 2.5–3.0); LMWH bridge when interrupting	[1–3,23,24]
Adult giant CAA—DOAC	Selective consideration with specialist oversight; pediatric evidence limited	[3,25]
After DES	DAPT 6–12 mo (shorter if HBR); if OAC needed, minimize triple therapy; prefer OAC + clopidogrel	[21,22]

AHA: American Heart Association; CAA: coronary artery aneurysm; INR: international normalized ratio; LMWH: low-molecular-weight heparin; DAPT: dual antiplatelet therapy; DOAC: direct oral anticoagulant; DES: drug-eluting stent; HBR: high bleeding risk; OAC: oral anticoagulation.